Clinical Trials
Phase I study of TTI-101, an oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with advanced cancers. CTMS#: 21-0019
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora MD